Phase 2Not yet recruiting
A Trial to Evaluate the Efficacy and Safety of ARO-INHBE in Adults With Metabolic Dysfunction-Associated Steatohepatitis
A Phase 2, Double-Blind, Placebo-Controlled Trial to Evaluate the Efficacy and Safety of ARO-INHBE in Adults With Metabolic Dysfunction-Associated Steatohepatitis With or Without Type 2 Diabetes Mellitus
- Sponsor
- Arrowhead Pharmaceuticals (Industry)
- Enrolment
- 252 planned
- Conditions
- Metabolic Dysfunction-Associated Steatohepatitis
- Interventions
- ARO-INHBE; Placebo
- Ages
- adults, older adults
- Registry
- NCT07859813
Full record on ClinicalTrials.gov
From the registry
This study is designed to evaluate the safety and efficacy of ARO-INHBE in adults with suspected metabolic dysfunction-associated steatohepatitis (MASH).
Primary outcomes
- Percent Change From Baseline in Liver Fat Content (LFC) by Magnetic Resonance Imaging-proton Density Fat Fraction (MRI-PDFF) at Week 48
History
Primary completion expected
Registered
Started